Results 311 to 320 of about 157,119 (339)
Some of the next articles are maybe not open access.

CXCR4 and Glioblastoma

Anti-Cancer Agents in Medicinal Chemistry, 2015
This article focuses on the possible application of antagonists of the G-protein coupled chemokine receptor, CXCR4, for the treatment of glioblastoma and summarises the evidence for CXCR4 antagonism being a viable therapeutic approach. Particular attention is paid to the role of this receptor in cancer stem cell biology, and the maintenance of CXCR4 ...
openaire   +2 more sources

CXCR4 in Clinical Hematology

2010
Pharmacological manipulation of CXCR4 has proven clinically useful for mobilization of stem and progenitor cells and in several preclinical models of disease. It is a key component in the localization of leukocytes and stem cells. For patients with multiple myeloma and non-Hodgkin's Lymphoma, treatment with plerixafor, an inhibitor of CXCL12 binding to
Gary, Calandra   +2 more
openaire   +2 more sources

The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.

Seminars in Cancer Biology, 2019
Single agent checkpoint inhibitor therapy has not been effective for most gastrointestinal solid tumors, but combination therapy with drugs targeting additional immunosuppressive pathways is being attempted.
S. Daniel, Y. Seo, V. Pillarisetty
semanticscholar   +1 more source

CXCR4 and cancer.

Pathology international, 2010
The chemokine receptor CXCR4 belongs to the large superfamily of G protein-coupled receptors and has been identified to play a crucial role in a number of biological processes, including the trafficking and homeostasis of immune cells such as T lymphocytes.
Bungo, Furusato   +3 more
openaire   +3 more sources

HIV coreceptor CXCR4 antagonists

Current Opinion in HIV and AIDS, 2006
Increases in HIV resistance towards approved antiviral drugs have made it necessary to develop new and potent antiviral drugs with preferably a novel mode of action.Entry inhibitors constitute a new class of drugs to treat infection by HIV-1. The first member of this class, enfuvirtide, previously known as T-20 and targeting gp41, has now been licensed
openaire   +2 more sources

CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy.

Immunology Letters, 2019
Chemokines are small molecules called "chemotactic cytokines" and regulate many processes like leukocyte trafficking, homing of immune cells, maturation, cytoskeletal rearrangement, physiology, migration during development, and host immune responses ...
A. Mousavi
semanticscholar   +1 more source

CXCR4: chemokine receptor extraordinaire

Immunological Reviews, 2000
Current investigations show that chemokine receptor CXCR4 is functionally expressed on a multitude of tissues and cell types, including different leukocyte subsets, hematopoietic progenitor cells and non-hematopoietic cells such as endothelial and epithelial cells.
openaire   +2 more sources

Human Melanoma Metastases Express Functional CXCR4

Clinical Cancer Research, 2006
Abstract Purpose: The chemokine receptor CXCR4 was identified as an independent predictor of poor prognosis in primary melanoma. The aim of the study was to investigate the role of CXCR4 in human melanoma metastases. Experimental Design: CXCR4 expression was evaluated in melanoma metastases and in metastatic cell lines ...
SCALA S.   +18 more
openaire   +7 more sources

Evaluation of Human and Rhesus CD34+CXCR4+ and CD34+CXCR4- Subpopulations

Blood, 2011
Abstract Abstract 1007 CXCR4 is an α-chemokine receptor specific for the ligand stromal-derived-factor-1 (SDF-1). CXCR4 is expressed on several cell types, including CD34+ cells. In this study, we sought to evaluate the difference between subpopulations of human and rhesus CD34+ cells that express CXCR4. Rhesus CD34+ cells
Naoya Uchida   +7 more
openaire   +1 more source

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Nature Medicine, 2020
B. Bockorny   +25 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy